Back

Initial clinical experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein (FLAP) inhibitor, intended for patients with coronary artery disease

27 August 2017 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Best Posters 3 - Best Posters in new targets in cardiovascular drug assessment Drug therapy ESC Premium Access ESC Congress 2017

About the speaker

Photo
Associate Professor Stanko Skrtic

Soborg (Sweden)

4 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor R. Turner (Durham, US)
Abstract Slides
Presentation thumbnail
Doctor M. Hatz (Munich, DE)
Abstract Slides
Presentation thumbnail
Doctor A. Almaghraby (Ras Al Khaimah, AE)
Abstract Slides

Access the full session

Session thumbnail
Best Posters 3 - Best Posters in new targets in cardiovascular drug assessment

The Event

Event poster

ESC Congress 2017

27 August 2017 14:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources